Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?
David E O'ReillyAngela BotticellaSimon BarrySeamus CotterJessica S DoningtonCecile Le PechouxJarushka NaidooPublished in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (2023)
For patients with non-small-cell lung cancer (NSCLC), the outcomes for patients with resectable disease are historically poor compared with other solid organ malignancies. In recent years, there have been significant advances in multidisciplinary care, which have resulted in improved outcomes. Innovations in surgical oncology include the use of limited resection and minimally invasive techniques. Recent data in radiation oncology have suggested refinements in pre- and postoperative radiation therapy, resulting in optimization of techniques in the curative setting. Finally, the success of immune checkpoint inhibitors and targeted therapies in the advanced setting has paved the way for inclusion in the adjuvant and neoadjuvant settings, resulting in recent regulatory approvals for four regimens (CheckMate-816, IMpower010, PEARLS, ADAURA). In this review, we will provide an overview of the seminal studies informing advancements in optimal surgical resection, radiation treatment, and systemic therapy for resectable NSCLC. We will summarize the key data on survival outcomes, biomarker analyses, and future directions for perioperative studies.
Keyphrases
- locally advanced
- radiation therapy
- small cell lung cancer
- minimally invasive
- rectal cancer
- healthcare
- patients undergoing
- electronic health record
- big data
- type diabetes
- early stage
- advanced non small cell lung cancer
- quality improvement
- deep learning
- lymph node
- liver metastases
- metabolic syndrome
- acute kidney injury
- radiation induced
- cardiac surgery
- case control